Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology.

[1]  W. Denny,et al.  3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel , 2019, Bioorganic & medicinal chemistry.

[2]  Christopher B. Cooper,et al.  Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline , 2019, Bioorganic & medicinal chemistry.

[3]  Alimuddin Zumla,et al.  Accelerating the development of therapeutic strategies for drug-resistant tuberculosis , 2018, Nature Reviews Drug Discovery.

[4]  R. Wallis.  Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine , 2016, European Respiratory Journal.

[5]  A. Diacon,et al.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis , 2015, European Respiratory Journal.

[6]  K. Dooley,et al.  Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment. , 2015, Future microbiology.

[7]  R. Hoetelmans,et al.  Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. , 2014, The Journal of antimicrobial chemotherapy.

[8]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[9]  W. Rom,et al.  New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline , 2014, Therapeutics and clinical risk management.

[10]  J. Avorn.  Approval of a tuberculosis drug based on a paradoxical surrogate measure. , 2013, JAMA.

[11]  K. Andries,et al.  Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207. , 2011, Future medicinal chemistry.

[12]  S. Franzblau,et al.  Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[13]  S. Franzblau,et al.  In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[14]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.